中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

328 records (took 0.019 seconds)

    삭사틸린-Ｆｃ 융합 단백질 및 이의 용도
    2.
    发明申请
    삭사틸린-Ｆｃ 융합 단백질 및 이의 용도 审中-公开
    SAXATILIN-FC融合蛋白及其用途

    公开(公告)号：WO2015016616A1

    公开(公告)日：2015-02-05

    申请号：PCT/KR2014/007013

    申请日：2014-07-30

    Applicant: 연세대학교 산학협력단

    Inventor： 홍성유 ,  허지회 ,  권일 ,  김동익 ,  장양수 ,  김영대

    IPC: C07K19/00 ,  C12N15/62 ,  A61K38/17 ,  A61P9/00

    CPC classification number: C07K14/46 ,  A61K38/00 ,  C07K2319/30 ,  C12N9/6489

    Abstract: 본 발명은 증가된 반감기를 가지는 삭사틸린 유도체 및 이의 용도에 관한 것이다. 본 발명의 삭사틸린 유도체는 모 단백질인 삭사틸린과 유사한 혈전 용해능을 가질 뿐 아니라 현저하게 증가된 단백질 반감기를 가지고, 이를 이용하여 FeCl 3 -유도된 경동맥 동물 모델에서 혈관 내 이미 형성된 혈전을 장기간 동안 매우 효율적으로 용해시킨다. 따라서, 본 발명의 삭사틸린 유도체를 유효성분으로 포함하는 조성물은 관통 후 재협착도 일으키지 않고, 미세혈관까지 효과적으로 개방시켜 혈관의 협착 또는 폐색 질환(예컨대, 뇌혈관질환, 심혈관질환, 동맥경화성 혈관질환, 관상동맥질환, 말초혈관질환, 등)의 치료에 매우 효과적이다.

    Abstract translation: 本发明涉及具有增加的半衰期的萨克西汀衍生物及其用途。 本发明的萨克西汀衍生物具有与作为母体蛋白质的萨克西林相似的溶血溶解能力，蛋白质半衰期显着增加，并且长时间有效地溶解已经在动物模型的血管中形成的血块 与FeCl3诱导的颈动脉通过使用它。 因此，含有作为活性成分的本发明的萨克西汀衍生物的组合物在渗透后不会引起再闭塞，并且有效地向微血管开放，因此对于治疗血管狭窄或闭塞性疾病（例如脑血管疾病，心血管疾病 ，动脉硬化血管疾病，冠状动脉疾病和外周血管疾病）。

    NOVEL MONOMERIC YELLOW-GREEN FLUORESCENT PROTEIN FROM CEPHALOCHORDATE
    3.
    发明申请
    NOVEL MONOMERIC YELLOW-GREEN FLUORESCENT PROTEIN FROM CEPHALOCHORDATE 审中-公开
    来自CEPHALOCHORDATE的新型单色黄绿色荧光蛋白

    公开(公告)号：WO2014018689A3

    公开(公告)日：2014-04-03

    申请号：PCT/US2013051911

    申请日：2013-07-24

    Applicant: ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS INC

    Inventor： LAMBERT GERARD C ,  NI YUHUI ,  WANG JIWU ,  SHANER NATHAN C

    IPC: A61K38/16 ,  A61K48/00

    CPC classification number: C07K14/46 ,  C07K14/43504 ,  G06F19/12 ,  G06F19/16

    Abstract: The present disclosure provides isolated nucleic acid sequences encoding a monomeric green/yellow fluorescent proteins, and fragments and derivatives thereof. Also provided is a method for engineering the nucleic acid sequence, a vector comprising the nucleic acid sequence, a host cell comprising the vector, and use of the vector in a method for expressing the nucleic acid sequence. The present invention further provides an isolated nucleic acid, or mimetic or complement thereof, that hybridizes under stringent conditions to the nucleic acid sequence. Additionally, the present invention provides a monomeric green/yellow fluorescent protein encoded by the nucleic acid sequence, as well as derivatives, fragments, and homologues thereof. Also provided is an antibody that specifically binds to the green/yellow fluorescent protein.

    Abstract translation: 本公开提供编码单体绿/黄荧光蛋白及其片段和衍生物的分离的核酸序列。 还提供了用于工程化核酸序列的方法，包含核酸序列的载体，包含载体的宿主细胞，以及用于表达核酸序列的方法中所述载体的用途。 本发明还提供了在严格条件下与核酸序列杂交的分离的核酸或其模拟物或补体。 此外，本发明提供由核酸序列编码的单体绿/黄荧光蛋白，以及其衍生物，片段及其同源物。 还提供了特异性结合绿色/黄色荧光蛋白的抗体。

    METHOD FOR REVERSING OR INHIBITING REPLICATIVE SENESCENCE
    7.
    发明申请
    METHOD FOR REVERSING OR INHIBITING REPLICATIVE SENESCENCE 审中-公开
    反转或抑制替代性感觉的方法

    公开(公告)号：WO2013038196A1

    公开(公告)日：2013-03-21

    申请号：PCT/GB2012/052273

    申请日：2012-09-14

    Applicant: ALJAMAL-NAYLOR, Rehab ,  NAYLOR, Robert

    Inventor： ALJAMAL-NAYLOR, Rehab ,  NAYLOR, Robert

    IPC: C07K16/28

    CPC classification number: C07K16/2842 ,  C07K14/46 ,  C07K2317/34 ,  C07K2317/70 ,  C07K2317/76

    Abstract: A method for inhibiting and/or reversing replicative senescence is provided comprising a step of administering a therapeutically effective amount of a compound which mediates allosteric modulation of beta 1 integrin to a subject in need thereof. Typically the allosteric modulation of beta 1 integrin results in beta 1 integrin assuming an intermediate affinity state conformation. The method of the present invention may be used in the treatment and/or prevention of ageing and ageing-related conditions.

    Abstract translation: 提供了一种用于抑制和/或逆转复制衰老的方法，其包括向有需要的受试者施用治疗有效量的介导β1整联蛋白的变构调节的化合物的步骤。 通常，β1整联蛋白的变构调节产生假设中间亲和态构象的β1整联蛋白。 本发明的方法可用于治疗和/或预防老化和老化相关的病症。

    METHOD FOR PERFORMANCE ANALYSIS AND SCREENING OF SEPTICAEMIA PROTEIN THERAPEUTIC AGENTS
    8.
    发明申请
    METHOD FOR PERFORMANCE ANALYSIS AND SCREENING OF SEPTICAEMIA PROTEIN THERAPEUTIC AGENTS 审中-公开
    分离蛋白质治疗药物的性能分析和筛选方法

    公开(公告)号：WO2012128577A3

    公开(公告)日：2013-01-24

    申请号：PCT/KR2012002091

    申请日：2012-03-22

    Applicant: KOREA RES INST OF BIOSCIENCE ,  KOREA ADVANCED INST SCI & TECH ,  LEE SEUNG GOO ,  KIM HAK SUNG ,  KIM YU JUNG ,  LEE SANG CHUL ,  HAN JI EUN ,  KIM SU JIN ,  SOHN JUNG HOON ,  HA JAE SEOK

    Inventor： LEE SEUNG GOO ,  KIM HAK SUNG ,  KIM YU JUNG ,  LEE SANG CHUL ,  HAN JI EUN ,  KIM SU JIN ,  SOHN JUNG HOON ,  HA JAE SEOK

    IPC: C12Q1/02 ,  C12N15/63 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68

    CPC classification number: C07K14/195 ,  C07K14/46 ,  C07K14/461 ,  C07K14/705 ,  C07K2319/35 ,  C07K2319/70 ,  C12N15/70 ,  C12Q1/6897 ,  G01N33/5023 ,  G06F19/16

    Abstract: The present invention relates to the construction of an assay system for analysing the performance of LRR (leucine rich repeat) proteins, that are constituted by the repeat combination of LRR modules, as septicaemia-inhibiting protein therapeutic agents, and for screening protein therapeutic agents that exhibit an outstanding inhibiting performance from a sequence variation library. More specifically, the present invention relates to: a performance analysis method or screening method for septicaemia protein therapeutic agents, comprising the step of adding purified MD-2 protein to an assay system using a cell line in which an LPS signal transmission receptor is expressed on the surface; a performance analysis method or screening method for septicaemia protein therapeutic agents, comprising the step of adding a purified foreign MD-2 protein to a THP-1 cell line; the cell line for performance analysis or for screening; and a kit for septicaemia therapeutic agent screening or performance analysis, comprising the cell line and purified foreign MD-2.

    Abstract translation: 本发明涉及用于分析LRR（富含亮氨酸重复）蛋白质的性能的测定系统的构建，其由LRR模块的重复组合构成，作为败血病抑制蛋白质治疗剂，并用于筛选蛋白质治疗剂， 从序列变异库显示出优异的抑制性能。 更具体地，本发明涉及：败血病蛋白治疗剂的性能分析方法或筛选方法，包括将纯化的MD-2蛋白加入到使用其中表达LPS信号传递受体的细胞系的测定系统的步骤 表面 用于败血病蛋白治疗剂的性能分析方法或筛选方法，包括将纯化的外源MD-2蛋白加入到THP-1细胞系中的步骤; 用于性能分析或筛选的细胞系; 以及用于败血症治疗剂筛选或性能分析的试剂盒，其包含细胞系和纯化的外源MD-2。

    NOVEL PEPTIDES WHICH HAVE ANALGESIC EFFECTS AND WHICH INHIBIT ASIC CHANNELS
    9.
    发明申请
    NOVEL PEPTIDES WHICH HAVE ANALGESIC EFFECTS AND WHICH INHIBIT ASIC CHANNELS 审中-公开
    具有镇痛作用并且抑制ASIC通道的新肽

    公开(公告)号：WO2012022894A4

    公开(公告)日：2012-04-12

    申请号：PCT/FR2011051800

    申请日：2011-07-26

    Applicant: CENTRE NAT RECH SCIENT ,  LINGUEGLIA ERIC ,  DIOCHOT SYLVIE ,  BARON-FORSTER ANNE ,  SALINAS MIGUEL ,  LAZDUNSKI MICHEL

    Inventor： LINGUEGLIA ERIC ,  DIOCHOT SYLVIE ,  BARON-FORSTER ANNE ,  SALINAS MIGUEL ,  LAZDUNSKI MICHEL

    IPC: C07K14/46

    CPC classification number: C07K14/46 ,  A61K38/00

    Abstract: The present invention relates to novel isolated peptides which induce analgesia and which inhibit ASIC channels (Acid Sensing Ion Channels), to the polynucleotides encoding said peptides, and also to the pharmaceutical compositions, host cells and vectors comprising same. In particular, said peptides are isolated from the venom of the snake Dendroaspis polylepis. The present invention also relates to the use thereof as a diagnostic tool or as medicament, and in particular as an analgesic, or for identifying analgesic molecules or molecules which inhibit ASIC channels.

    Abstract translation: 本发明涉及诱导镇痛并且抑制ASIC通道（酸敏感离子通道）的新型分离的肽，涉及编码所述肽的多核苷酸，以及包含其的药物组合物，宿主细胞和载体。 具体而言，所述肽从蛇Dendroaspis polylepis的毒液中分离。 本发明还涉及其作为诊断工具或用作药物，特别是作为镇痛剂，或用于鉴定抑制ASIC通道的镇痛分子或分子的用途。

Patent Agency Ranking